Abstract

Background Human noroviruses are a major cause of epidemic and sporadic gastroenteritis worldwide and can chronically infect immunocompromised patients. Efforts to develop effective vaccines and antivirals have been hindered by the uncultivable nature and extreme genetic diversity of human noroviruses [1]. Previous therapies have focused on targeting nucleases and structural proteins. The norovirus RNA genome or viral transcripts also constitute an important target to inhibit the replication of norovirus. Finding a conserved component of the Norovirus genome would make it an ideal target that could overcome the genetic diversity of strains [2]. Gene-based therapy is the intentional modulation of gene expression in specific cells to treat pathological conditions. This modulation is accomplished by introducing exogenous nucleic acids such as small interfering RNA (siRNA). Given the large size and negative charge of this macromolecule, its delivery is typically mediated by carriers or vectors. Targeting the gastrointestinal (GI) tract represents a promising strategy for local or systemic delivery of gene-based therapeutics [3].

Highlights

  • Human noroviruses are a major cause of epidemic and sporadic gastroenteritis worldwide and can chronically infect immunocompromised patients

  • Two candidate sequences of the RdRP were identified for small interfering RNA (siRNA) mediated inhibition

  • This report reviews the possibility of siRNA-mediated inhibition of the RNA norovirus genome and the challenges that an oral gastrointestinal-delivery system will face

Read more

Summary

Introduction

Human noroviruses are a major cause of epidemic and sporadic gastroenteritis worldwide and can chronically infect immunocompromised patients. Results The Sydney 2012 genotype was found to be the most prevalent virus strain in Ireland and the RNA dependant RNA polymerase (RdRp) was found to be a conserved component. Two candidate sequences of the RdRP were identified for siRNA mediated inhibition.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call